12 research outputs found
National Mass Drug Administration Costs for Lymphatic Filariasis Elimination
Lymphatic filariasis (LF), commonly known as elephantiasis, is a profoundly disfiguring parasitic disease caused by thread-like nematode worms. This disease can often be disabling, thus reducing the potential productivity of the affected individuals. The WHO places the number of people at risk in 83 countries at 1.307 billion. This study was undertaken in seven countries—Burkina Faso, Ghana, Egypt, Tanzania, the Philippines, the Dominican Republic, and Haiti—using a common protocol to determine the costs of mass drug administration (MDA) programs to interrupt transmission of infection with LF, because there is lack of sufficient information about the costs of these programs. The results demonstrate that LF MDA is affordable and relatively inexpensive when compared to other public health programs. In the context of initiatives for integrating programs for the control and elimination of neglected tropical diseases, this study adds specifically to the relatively scarce body of information about the costs of MDA programs for LF. It also adds to the general knowledge about the application of methods that can be used to estimate the costs and cost-effectiveness of an integrated approach
Country Background Information.
a<p>(World Health Organization 2002, World Health Organization 2003, World Health Organization 2004a).</p
Costs by Activity – Percentage of Financial Costs for a ‘Non-Start-Up’ MDA Round.
1<p>Major expenditures for mapping activities predated the years covered by the cost studies.</p>2<p>Average of district and central levels.</p>3<p>Haiti and the Dominican Republic distributed training costs across the activities.</p>4<p>Governorate level.</p
Financial Costs and Population Treated by Country and MDA Year.
<p>Financial Costs and Population Treated by Country and MDA Year.</p
Costs by Input – Percentage of Financial Costs for a ‘Non-Start-Up’ MDA Round.
<p>Costs by Input – Percentage of Financial Costs for a ‘Non-Start-Up’ MDA Round.</p